A085660 Stock Overview
A bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Chabiotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,860.00 |
| 52 Week High | ₩21,000.00 |
| 52 Week Low | ₩13,350.00 |
| Beta | 0.19 |
| 1 Month Change | -2.24% |
| 3 Month Change | -15.33% |
| 1 Year Change | -26.25% |
| 3 Year Change | -21.79% |
| 5 Year Change | 4.28% |
| Change since IPO | 99.10% |
Recent News & Updates
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?
Nov 12
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business
Aug 07Recent updates
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?
Nov 12Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business
Aug 07Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?
Mar 01If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%
Jan 25The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About
Dec 21Shareholder Returns
| A085660 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | -3.8% | -4.8% | -3.7% |
| 1Y | -26.3% | -22.0% | -10.4% |
Return vs Industry: A085660 underperformed the KR Healthcare industry which returned -22% over the past year.
Return vs Market: A085660 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
| A085660 volatility | |
|---|---|
| A085660 Average Weekly Movement | 5.2% |
| Healthcare Industry Average Movement | 9.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A085660 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A085660's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 292 | Hoon Oh Sang | www.chabio.com |
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.
Chabiotech Co.,Ltd. Fundamentals Summary
| A085660 fundamental statistics | |
|---|---|
| Market cap | ₩831.77b |
| Earnings (TTM) | -₩2.60b |
| Revenue (TTM) | ₩1.01t |
0.8x
P/S Ratio-319.7x
P/E RatioIs A085660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A085660 income statement (TTM) | |
|---|---|
| Revenue | ₩1.01t |
| Cost of Revenue | ₩749.63b |
| Gross Profit | ₩260.17b |
| Other Expenses | ₩262.77b |
| Earnings | -₩2.60b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -46.49 |
| Gross Margin | 25.76% |
| Net Profit Margin | -0.26% |
| Debt/Equity Ratio | 77.6% |
How did A085660 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 00:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chabiotech Co.,Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Sang-Hun Lee | iM Securities |
| Jung-In Lee | Korea Investment & Securities Co., Ltd. |